HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization - evidence from cell line and patient derived xenograft models

PURPOSE: Our previous work suggested that HER3 inhibition sensitizes HNSCC to EGFR inhibition with cetuximab. This study aimed to define the role of HER3 in cetuximab resistance and the anti-tumor mechanisms of EGFR/HER3 dual targeting in HNSCC. EXPERIMENTAL DESIGN: We treated cetuximab-resistant HN...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Wang, Dongsheng, Qian, Guoqing, Zhang, Hongzheng, Magliocca, Kelly R., Nannapaneni, Sreenivas, Amin, A.R.M. Ruhul, Rossi, Michael, Patel, Mihir, El-Deiry, Mark, Wadsworth, J Trad, Chen, Zhengjia, Khuri, Fadlo R., Shin, Dong M., Saba, Nabil F., Chen, Zhuo G.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5199640/
https://ncbi.nlm.nih.gov/pubmed/27358485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0558
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares